Author(s): Mednick LM, Braunstein J, Neufeld E
Abstract Share this page
Abstract Deferasirox, the only oral iron chelator approved in the US and Canada, achieved a pediatric label indication down to 2 years of age. FDA-mandated post-marketing safety surveillance in children under age 6 is ongoing. We wish to raise a non-safety-related concern with deferasirox chelation in very young children (2-5 years old). Specifically, the circumstances required for reliable daily ingestion of deferasirox do not mesh well with the developmental characteristics common in young children, which may limit adherence and cause parental distress. We review developmental challenges associated with oral chelation in this age group and provide suggestions to improve adherence in this population. Copyright 2010 Wiley-Liss, Inc.
This article was published in Pediatr Blood Cancer
and referenced in Journal of Blood Disorders & Transfusion